Literature DB >> 10669378

Chlamydia pneumoniae-induced transactivation of the major immediate early promoter of cytomegalovirus: potential synergy of infectious agents in the pathogenesis of atherosclerosis.

C Wanishsawad1, Y F Zhou, S E Epstein.   

Abstract

Both cytomegalovirus (CMV) and Chlamydia pneumoniae have been associated with atherosclerosis. CMV is believed to exist in host tissues in a latent state with periodic reactivation. This study was designed to determine whether C. pneumoniae infection stimulates the expression of CMV genes. Transactivation of the CMV major immediate early promoter (MIEP) is essential for viral gene expression and viral replication. HeLa cells were transfected with a construct containing a reporter gene (chloramphenicol acetyl transferase) controlled by the MIEP. The cells were then infected with Chlamydia at 102-106 infection-forming units (IFU) per well at various times before assay of MIEP activity (72 h after transfection). Peak transactivation occurred 6 h after infection at 104 IFU. C. pneumoniae increased MIEP activity in a dose-response manner; maximal increase was >2-fold. These results suggest that if CMV and C. pneumoniae do indeed contribute to atherosclerosis, their copresence may synergistically contribute to it.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669378     DOI: 10.1086/315235

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Chlamydia pneumoniae exacerbates aortic inflammatory foci caused by murine cytomegalovirus infection in normocholesterolemic mice.

Authors:  K Burian; K Berencsi; V Endresz; Z Gyulai; T Valyi-Nagy; I Valyi-Nagy; M Bakay; Y Geng; D Virok; L Kari; R Hajnal-Papp; G Trinchieri; E Gonczol
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

Review 2.  Potential infectious etiologies of atherosclerosis: a multifactorial perspective.

Authors:  S O'Connor; C Taylor; L A Campbell; S Epstein; P Libby
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

3.  Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.

Authors:  Mark Loeb; Hisham Dokainish; Antonio Dans; Lia M Palileo-Villanueva; Ambuj Roy; Kamilu Karaye; Jun Zhu; Yan Liang; Fastone Goma; Albertino Damasceno; Khalid F AlHabib; Gerald Yonga; Charles Mondo; Wael Almahmeed; Arif Al Mulla; Salim Yusuf
Journal:  Am Heart J       Date:  2019-03-11       Impact factor: 4.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.